Cancer BiologyNature CancerPeer-reviewed
Structural and functional analysis of lorlatinib analogs reveals roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer
A. Shiba-Ishii, T. W. Johnson, I. Dagogo-Jack…·A. N. Hata
This study identifies lorlatinib-resistant ALK mutations and evaluates analogs to develop targeted therapies for compound resistance in ALK-positive lung cancer.
DOI 10.1038/s43018-022-00399-6